Gene therapy for SCID-X1

gene therapy

Gene therapy for SCID-X1

A new gene therapy study in New England Journal of Medicine reports positively on the use of a self-inactivated  lentivirus (i.e. a lentivirus deleted of long terminal repeat (LTR) sequences containing potential viral transcriptional elements) supplemented by an insulator and a codon-optimised human common γ chain (γc) gene (also known as IL2RG or Interleukin 2 receptor subunit gamma) to treat X-linked severe combined immunodeficiency (SCID-X1) or “bubble boy” disease.

After around 16 months of follow-up, results from eight treated patients show reconstitution of functional T cells and B cells, and normalization of NK-cell counts.

Vector site integration data generally showed polyclonal pattern, but long term follow-up will be needed to show absence of vector-induced leukaemia to complement the promising data.

The eRA Conference 2019 started today!
EU measures in support of generic pharmaceuticals producers

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

Aviso de cookies